Recruitment is now complete for this study which aims to evaluate the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus a placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
This trial was for women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer; confirmed biomarker PIK3CA mutation; they must have progressed during adjuvant treatment or within 12 months of completing endocrine therapy. Patients with bone only disease or history of type 1 or 2 diabetes are excluded.
Palmerston North Hospital was the only New Zealand site and all participants are now in follow-up.
More trial information is available here.
12 November 2024
